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ABSTRACT
Background. Human Metapneumovirus (hMPV) is a negative single-stranded RNA
virus. Infection by hMPV mainly affects the pediatric population and can cause upper
or lower respiratory tract pathologies which can develop life threating complications.
This studywas carried out between 2009 and 2010 in a high complexity national hospital
in Lima, Peru. The time frame corresponds to the pandemic of influenza A H1N1.
Methods. A prospective study was performed between September 2009 and September
2010. Patients with a clinical diagnosis suggestive of an acute respiratory infection were
included. RT-PCR was utilized to attain the amplification and identification of the
hMPV.
Results. A total of 539 samples were analyzed from patients with a clinical context
suggestive of an acute respiratory tract infection. Of these samples 73, (13.54%) were
positive for hMPV. Out of the positive cases, 63% were under one year old, and
increased to nearly 80% when considering children younger than two years old. Cough
was the most frequent symptom presented by our population with a number of 62
cases (84.93%). Viral seasonality was also established, noting its predominance during
the months of summer in the southern hemisphere. The infection by hMPV has an
important prevalence in Peru. It mainly affects children under one year old and should
be considered an important differential diagnosis in a patient with an acute respiratory
infection.
SubjectsMolecular Biology, Virology, Pediatrics, Respiratory Medicine
Keywords Acute respiratory tract infection, Pediatrics, Polymerase chain reaction, Acute
obstructive bronchitis, Human metapneumovirus, Peru
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INTRODUCTION
The Human Metapneumovirus (hMPV) is a negative single-stranded RNA virus. It
belongs to the family Pneumoviridae, which includes the genus Metapneumovirus
and Orthopneumovirus, whose main representatives are the Human Metapneumovirus
(hMPV) and the Respiratory Syncytial Virus, respectively (Van den Hoogen et al., 2003).
The hMPV was initially isolated and described in the Netherlands during the year 2001;
however, it is presumed that hPMV is responsible for respiratory infections dating back
to approximately six decades (Van den Hoogen et al., 2003; Boivin et al., 2002; Nissen et al.,
2002; Peret et al., 2002; Boivin et al., 2004). According to the phylogenetic analysis, within
the most frequent isolated genotypes, two subgroups of hPMV have been identified: A and
B, which include subtypes A1, A2, B1 and B2 (Boivin et al., 2004;Mackay et al., 2006).
Infection due to hMPV mainly affects the pediatric population and can cause diverse
pathologies of the upper or lower respiratory tract, which include rhinopharyngitis,
laryngitis, croup, pneumonia, bronchiolitis or asthma exacerbations (Williams et al., 2004;
Boivin et al., 2007). Furthermore, it also affects the adult population, predominantly elderly
and immunosuppressed patients (Boivin et al., 2007). Although the clinical context most
frequently consists of an asymptomatic period that lasts approximately seven days post
exposure, followed by a week of symptoms of an upper respiratory tract infection with
gradual resolution, the clinical course can progress toward the lower respiratory tract
resulting in lung parenchymal involvement and cause further complications (Boivin et
al., 2003; Falsey et al., 2003; Mullins et al., 2004; Xepapadaki et al., 2004; Schlapbach et al.,
2011). It is estimated that infections caused by hMPV are accountable for approximately
20,000 hospitalizations per year in children under five years old in the United States
(Edwards et al., 2013). However, the available information regarding its epidemiology is
limited due to a deficient suspicion and its clinical similarity with other respiratory viruses
such as the Influenza virus and the Respiratory Syncytial Virus. It has been described
and established in Western countries that the prevalence of the Human Metapneumovirus
increases during the late winter months and the beginning of the spring; however, it has also
been reported during late spring and summermonths in cities such as Hong Kong (Van den
Hoogen et al., 2003; Williams et al., 2004; Peiris et al., 2003; Døllner et al., 2004; Haynes et
al., 2016). Currently, the limited availability of molecular methods for the precise diagnosis
of viral pathologies such as those caused by hMPV leads to poor epidemiological data in
Latin American countries such as Peru. The aim of this study is to identify the Human
Metapneumovirus responsible for acute respiratory infections in children from September
2009 to September 2010 in Lima, Peru.
MATERIALS AND METHODS
Patients
We performed a prospective study between September 2009 and September 2010 in a
high complexity national hospital in Lima, Peru. The time frame corresponds to the
pandemic of influenza A H1N1. In this study we included all the patients with clinical
diagnosis of acute respiratory infections (ARI). We use the operative definition of ARI,
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according to the sanitary directives of the Ministry of Health of Peru, as any infection
that involves one or more parts of the respiratory system, with a duration of less than
14 days and with the presence of one or more clinical signs: cough, rhinorrhea, nasal
obstruction, odynophagia, dysphonia, otalgia, noisy breathing, respiratory distress, which
may or may not be accompanied by fever. The epidemiological and clinical data were:
age, clinical symptoms (fever: defined as temperature higher than 38 ◦C, rhinorrhea,
cough, respiratory difficulty, sore throat, wheezing, discomfort, pharyngeal congestion,
expectoration, vomiting, diarrhea, others.).
Ethics statement
Samples were collected following a written informed consent signed by all the parents
or respective caregiver because the patients were under 18 years of age. This study has
been approved by two independent Ethics Committees from Hospital Nacional Cayetano
Heredia (Ethical Application N◦ 021-09) and Instituto de Investigación Nutricional (Ethical
Application N◦ 279-2009 / CEI-IIN) in Lima, Peru.
Samples
To obtain the samples we used two different swabs. A first swab was inserted into both
nostrils parallel to the palate to obtain the nasopharyngeal samples (Mini-Tip Culture
Direct; Becton-Dickinson Microbiology System, Franklin Lakes, NJ, USA). The second
swab was inserted into the posterior pharyngeal and tonsillar areas (Viral Culturette;
Becton-DickinsonMicrobiology Systems, Franklin Lakes, NJ, USA). A tube containing viral
transport medium (minimal essential medium with 2% fetal bovine serum, amphotericin
B 20 µg/ml, neomycin 40 µg/ml,) was used to store both swabs. Two aliquots of each fresh
specimen were stored at −20 ◦C to be later analyzed for hMPV.
RNA extraction
The viral genetic material was extracted used the High Pure RNA Isolation Kit (Roche
Applied Science, Mannheim, Germany) to perform the RNA extraction from 200 µL of
the samples, according to the manufacturer’s instructions. Viral RNA obtained after the
extraction was eluted in 100 µl of nuclease-free water.
Reverse Transcriptase Polymerase chain reaction (RT-PCR) for the
analysis of Human Metapneumovirus (hMPV)
A one-step RT-PCR was performed using Real Time ready RNA Virus Master (Roche
Diagnostic, Deutschland-Mannheim, Germany) and 250 nM specific primers for hMPV
in a final volume of 20 µL. The primers were described by Van den Hoogen et al. (2003),
amplifying a conserved fragment of 170 nt in the polymerase chain. Five microliters of the
extracted RNA was combined with 15 µl of the master mix and the reverse transcription
step was performed 45 ◦C for 45min and the amplification consisted of an initial incubation
at 95 ◦C for 2 min, followed by 45 cycles of 95 ◦C for 1 min; 50 ◦C for 1 min, and 72 ◦C for
30 s; with a final extension at 72 ◦C for 10 min.
Amplified products were recovered from the gel, purified (SpinPrep Gel DNA Kit; San
Diego, CA) and sent for commercial sequencing (Macrogen, Seoul, South Korea).
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Table 1 Frequency and prevalence of the hMPV infection.
Cases PCR
Frequency (N) Prevalence (%) [CI 95%] Odds [CI 95%] Odds ratio [CI 95%]
Positives 73 13.54 [10.91–16.69] 0.16 [0.11–0.20] 0.03 [0.01–0.06]
Negatives 466 86.46 [83.31–89.09] 6.38 [5.14–7.92]
Total 539 100.00
Statistic analysis
The data was registered in a database designed in Access and were exported to an Excel file
for further analysis. The tabulated data were shown as percentage frequencies or counts.
The graphics were prepared with the OriginPro v8 software, and analyzed with the Minitab
v18 software.
RESULTS
A total of 539 samples belonging to patients with a clinical context suggestive of an acute
respiratory tract infection were analyzed. Of these samples, 73 were positively identified
using RT-PCR for hMPV. This finding establishes a prevalence of 13.54% for hMPV in the
population studied. Nonetheless, the probability or risk of associating a clinical course of
a symptomatic acute respiratory tract infection to the presence of hMPV was less than 3%
as demonstrated by the calculated OR (Table 1). This result suggests that other etiological
agents (p.e. RSV, influenza, etc.) have a greater probability to be present in the setting of
an acute respiratory tract infection (Appak et al., 2018; Brini Khalifa et al., 2018).
This study also found that 63% of the positive cases for hMPV identified through
PCR corresponded to children under one year of age, and this percentage increased to
around 80% when considering children under two years of age. The same distribution was
observed in the total cases for acute respiratory tract infections. Thus, in both cases, the
age distribution can be adjusted to exponential models (Fig. 1A) and where it can clearly
be seen that acute respiratory tract infections are more frequent children under two years
of age. Additionally, it can be indicated that the sex of children is not a factor associated
with the prevalence of hMPV (Fig. 1B).
More than 90%of children diagnosedwith an hMPV respiratory tract infection identified
positively by PCR were hospitalized. In these patients, the most common signs and
symptoms were cough which was present in 84.93% cases (n= 62), followed by fever
with 75.34% (n= 55) and rhinorrhea 71.23% (n= 52). In addition, 51 patients (69.86%)
presented with dyspnea. This distribution of signs and symptoms was similar for both the
population of children with a negative PCR for hMPV, and for all the children clinically
diagnosed with an acute respiratory tract infection (Fig. 2A). It is important to note that of
the total of cases studied (n= 539), mortality was observed in three patients who happened
to be negative via PCR for hMPV infection.
Figure 2B, shows the correlation analysis of the signs and symptoms identified in the
group of positive patients for hMPV identified through PCR and the total of patients
with an acute respiratory tract infection. Also, between positive and negative patients for
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Figure 1 Distribution of patients by age (A) and sex (B).
Full-size DOI: 10.7717/peerj.7266/fig-1
hMPV identified through PCR. Clearly, it is observed that in all these cases there is a high
correlation (r ∼1). This emphazises that a patientwith a respiratory tract infection caused by
hMPV, can present a wide range of signs and symptoms which can hardly be discriminated
from a clinical diagnosis of an acute respiratory tract infection. Respiratory tract infections
caused by hMPV have been described as a seasonal pattern of infectious disease (Appak et
al., 2018; Brini Khalifa et al., 2018). Figure 3 shows the monthly and seasonal distribution
of the acute respiratory tract infections cases and those with a positive PCR for hMPV.
The cases of hMPV appear in the month of December 2009 (n= 10), increased during the
month of January 2010 (n= 15) and the highest number of positive cases were recorded
during the month of March 2010 ( n= 21) coinciding with the maximum number of cases
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Figure 2 Clinical symptoms. Frequency distribution (A) and correlation analysis (B).
Full-size DOI: 10.7717/peerj.7266/fig-2
diagnosed clinically as an acute respiratory tract infection. Seasonality (in this hemisphere)
corresponds to 42 cases during the months of summer, 21 cases were reported in the fall
and spring was the season with the least prevalence of cases (n= 3) (Fig. 3).
DISCUSSION
After its first identification and description in 2001, theHumanMetapneumovirus (hMPV)
has been detected in patients with respiratory tract infections in Europe, Asia, Oceania,
Africa, South America (Hamelin, Abed & Boivin, 2004;Druce et al., 2005). In Peru, between
the years 2002 and 2003, genotype B1 was isolated by RT-PCR in mainly patients under
five years old (Gray et al., 2006). Nonetheless, due to the clinical course similarity it shares
with other respiratory viruses it presents as an obstacle for healthcare providers at the
time of establishing the etiological diagnosis of the disease. Therefore, its incidence, most
affected population, most frequent clinical presentation and seasonal distribution are not
well determined. In the present study, 73 cases were isolated during the 13 months in
which samples from patients with a clinical course similar to an influenza infection were
evaluated. Of the sampled analyzed 13.54% were positive via PCR for hMPV infection,
which represents a percentage that merits consideration of hMPV infection as a differential
diagnosis in patients with the aforementioned clinical picture. The available information
on seroprevalence suggests that the majority of patients have been infected before the age
of five (Van den Hoogen et al., 2003). Various studies report a prevalence between 5% and
15% in the pediatric population with a clinical course similar to influenza (Williams et al.,
2004; Boivin et al., 2003; Døllner et al., 2004; Esper et al., 2004; Louie et al., 2007; Schuster et
al., 2015;Corti et al., 2013; Bhattacharyya et al., 2015;Williams et al., 2006). It is also known
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Figure 3 Monthly distribution of cases. The gray box indicates the months of greatest incidence. Inset,
seasonal distribution.
Full-size DOI: 10.7717/peerj.7266/fig-3
that the majority of cases correspond to children under one year of age and that early age is
associated with greater need for hospitalization (Edwards et al., 2013). The findings in the
present study are consistent with the literature reviewed, in which 63.01% of positive cases
correspond to children under 1 year and 84.93% of cases belong to children under five years
old. In relation to the symptoms presented by our study population, (Williams et al., 2004;
Edwards et al., 2013; Esper et al., 2004) the most frequent symptom was cough, a finding
that coincides with our study, in which this symptom was observed with a frequency of
84.93% in the patients who were positive for hMPV. The second most frequent symptom
found in our studywas fever (75.34%); however, according to different studies it can present
with a prevalence ranging from 52% to 86% depending on the series. On the other hand,
dyspnea was identified in 69.86% of the patients, which indicates that the lower respiratory
tract is usually compromised. In addition, although the classical theory on viral replication
suggests that hMPV infection is limited to the respiratory tract, cases have been reported
of viral encephalitis in children with respiratory tract infections by hMPV, in which the
virus has been isolated postmortem from the cerebrospinal fluid (CSF) (Madhi et al., 2006;
Schildgen et al., 2005). Of the total number of samples analyzed, four samples came from
patients with a clinical diagnosis of Encephalitis; however, after rigorous analysis, none was
positive for hMPV infection. It has been described that HumanMetapneumovirus infection
can cause exacerbations of obstructive conditions such as Asthma and Chronic Obstructive
Pulmonary disease (Williams et al., 2005; Vicente et al., 2004; Beckham et al., 2005). This is
important in the context of respiratory infections caused by viruses such as RSV that cause
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Bronchiolitis in the pediatric population and it has been associated to the development
or susceptibility to suffer from asthma in the future (Openshaw, Dean & Culley, 2003). In
addition, the possibility of partial cross-immunity between both viruses is evaluated, since
monoclonal antibodies are capable of neutralizing RSV and hMPV (Schuster et al., 2015;
Corti et al., 2013). The diagnosis of an infection caused by hMPV can be made through
serology, direct immunofluorescence, viral culture and RT-PCR. Currently, molecular
diagnosis by RT-PCR, either conventional or real-time, offers the highest sensitivity than
the rest of diagnostic methods previously described (Van den Hoogen et al., 2003;Williams
et al., 2004; Boivin et al., 2003; Falsey et al., 2003; Esper et al., 2004). In the present study, all
the samples were analyzed via RT-PCR to establish the diagnosis of hMPV infection. The
seasonality of the virus was observed in the majority of studies during the spring season
in western countries; however, in the present study, 57.53% of cases occurred during
the summer months, with the month of March exhibiting the highest number of cases
(n= 21). This finding could be partly explained because more than 80 ARIs were reported
during that month, a higher number than any other period during the study. This finding
emphasizes the importance of describing the seasonal behavior of hMPV and respiratory
viruses that cause similar respiratory clinical courses, so that doctors can use as a tool to
make more targeted diagnoses.
A limitation in this study was that we did not evaluate other viral or bacterial etiological
agents that could be responsible for coinfections. The clinical characteristics in the presence
of coinfection could differ from those with unique infection by hMPV. Another limitation
is that the type of sampling in our study supposes a potential selection bias. However,
due to our interest in studying the presence of hMPV in patients with ARI, it was the
most feasible and efficient sampling selection approach for the context in which it was
performed.
CONCLUSION
Respiratory tract infections caused by hMPVhas an important prevalence in LatinAmerican
countries, such as Peru. It mainly affects children under one year old and can cause upper
and lower respiratory tract infections. It is important to conduct further studies and to
provide sustained epidemiological surveillance that allows the attending physician to have
the pertinent information available to suspect an infection by hMPV. Moreover, molecular
diagnostic methods such as RT-PCR still require standardization; however, it would be
ideal if they were available in reference laboratories from all health care facilities in order
to provide a specific etiologic diagnosis with the best sensitivity and specificity available.
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